Client News
Bionor Sees Promise of Two Core Platform Technologies
Bionor Pharma ASA today announced that its submission has been completed for two applications of Intellectual Property that will provide general platform protection for the Company’s development of peptide vaccines for cellular immunity.
New HIV Research Findings to Be Presented at NAPWA “Treatment Horizons: Pathways to a Functional Cure” Symposium, IAS Conference, Rome
New HIV Research Findings to Be Presented at NAPWA “Treatment Horizons: Pathways to a Functional Cure” Symposium, IAS Conference, Rome
Researchers to Present Results From Two VIRxSYS HIV Studies at the 6th International AIDS Society Meeting
NEWS: Researchers to Present Results From Two VIRxSYS HIV Studies at the 6th International AIDS Society Meeting
NEWS: WHITECOAT Wins Communicator Award for Video Produced for BIO
NEWS: WHITECOAT Wins Communicator Award for Video Produced for BIO
Environmental, Conservation Group Experts Join Bioethicists, University Researchers, and Scientists From Tree Growing Industry to Issue First-Ever Principles for the Responsible Use of Biotech Trees
NEWS: First-Ever Principles Issued for the Responsible Use of Biotech Trees
Vacc-4x shows statictically significant reduction in viral load
NEWS: Vacc-4x shows statictically significant reduction in viral load
WHITECOAT Strategies Wins Gold Medal
NEWS: WHITECOAT Strategies Wins Gold Medal for Best PR Video of the Year from TIVA-DC PEER Awards
New CEO of Bionor Pharma ASA
NEWS: Henrik Lund MD PhD, Former Global VP in Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA
Early Vacc-4x Results
NEWS: Two Thirds of Study Volunteers Respond to First-Ever “Re-Vaccination” of Vacc-4x
Bionor Immuno’s Therapeutic HIV Vaccine Candidate Vacc-4x
NEWS: Bionor Immuno’s Therapeutic HIV Vaccine Candidate Vacc-4x Targeting Conserved Domains of HIV Produce Immune Response Seven Years After Inoculation
Recent Comments